Geneva, Switzerland and Boston, MA – July 15, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…
Month: July 2020
The mechanism of action of oxytocin receptor antagonists (OTRan) in ART – a study of nolasiban on biomarkers of uterine receptivity in healthy female volunteers
O. Pohl, L. Marchand, P. Pierzyński, C. Blockeel, S. Mackens, U. Lorch, J.P. Gotteland
ESHRE 36th Virtual Annual Meeting, 5-8 July 2020
Human Reproduction, Volume 35, Issue Supplement_1, July 2020, on pages i83–i84
Efficacy and safety of linzagolix on heavy menstrual bleeding (HMB) due to uterine fibroids (UF): Results from a placebo-controlled, randomized, Phase 3 trial
H. Taylor, J. Donnez, R. Taylor, E. Bestel, J.P. Gotteland, A. Humberstone, E. Garner
ESHRE 36th Virtual Annual Meeting, 5-8 July 2020
Human Reproduction, Volume 35, Issue Supplement_1, July 2020, on page i13
ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 7, 2020
ObsEva SA to present at ESHRE Virtual 36th Annual Meeting July 6, 2020: Click ‘Read More’ to access link on ESHRE Platform
Investor Presentation Conference Call 6th July, 2020
ObsEva SA to Hold Conference Call Monday, July 6 to Discuss Results from Phase 3 PRIMROSE 1 and PRIMROSE 2 Trials Evaluating Linzagolix in Women with Uterine Fibroids
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24 PRIMROSE…
Linzagolix UF
(OBE2109)
Oral GnRH
receptor antagonist
ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020
Geneva, Switzerland and Boston, MA – July 3, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…